LivaNova (LIVN)

Its cardiopulmonary business provides equipment and consumables used during cardiac surgery and other procedures that require temporary support of heart and lung function. Products in this area include heart-lung machines, oxygenators, perfusion systems, and related devices used by surgical teams in operating rooms. This segment connects LivaNova to hospital capital spending, procedure volumes, and the need for reliable life-support technology during high-risk interventions.

The company’s neuromodulation business is centered on vagus nerve stimulation therapy. These implantable systems are used as treatment options for patients with drug-resistant epilepsy and are also associated with therapy for difficult-to-treat depression in certain markets. This gives LivaNova a position in neurological disorders where conventional medication does not adequately control symptoms for some patients.

Following its formation, LivaNova narrowed its portfolio by divesting several businesses, including cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation operations. The result is a more focused medical device company with a meaningful presence in the United States, Europe, and other international markets.

For investors, LivaNova represents exposure to specialized medical devices where product reliability, regulatory approvals, clinical data, and physician adoption are central to long-term performance.